LB Pharmaceuticals Inc has priced its upsized initial public offering of 19,000,000 shares at $15.00 per share, expecting gross proceeds of $285.0 million. The company granted underwriters an option to purchase up to 2,850,000 additional shares. Trading on the Nasdaq Global Market under “LBRX” starts on September 11, 2025, with the offering closing on September 12, 2025. Leerink Partners, Piper Sandler, and Stifel are the joint bookrunning managers. LB Pharmaceuticals is developing therapies for schizophrenia and bipolar depression, with lead product candidate LB-102 potentially becoming the first benzamide antipsychotic approved for neuropsychiatric disorders in the U.S.

Read more at GlobeNewswire: LB Pharmaceuticals Announces Pricing of its Upsized Initial